Q-omics provides the consensus-scored LEMD2 profile across patient tissues and cancer cell-line models. LEMD2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, LEMD2 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, LEMD2 RNA expression shows 19,391 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THYM, HNSC, and ACC as cancer lineages where LEMD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LEMD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LEMD2 survival associations across molecular data types. LEMD2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LEMD2 RNA expression–survival associations across cancer types. High LEMD2 expression shows unfavorable associations in ACC, LIHC, LGG, KIRP and BRCA, but favorable associations in THYM. The THYM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for LEMD2 RNA expression.
This table summarizes LEMD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LEMD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LEMD2 shows higher tumor expression in HNSC, KIRC, BLCA, LIHC, KIRP and STAD. The HNSC box plot shows higher LEMD2 RNA expression in tumor versus normal tissue (log2 FC = +1.130, t-test p < 0.001).
This table shows molecular features associated with LEMD2 in patient tissues and cancer cell lines. In patient samples, LEMD2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LEMD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
